EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

NUDT15 Genetic Polymorphism as a Risk Factor for Early Neutropenia During Valganciclovir Prophylaxis in Lung Transplant Patients

Yurie Katsube iD, Keisuke Umemura, Yuzuki Urabe, Miori Ono, Yoshiki Katada, Daiki Hira, Akihiro Ohsumi, Daisuke Nakajima, Masahiro Tsuda, Shunsaku Nakagawa, Tomoyuki Mizuno, Miki Nagao und 2 weitere

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Yurie Katsube und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Lung Transplantation, Neutropenia, Valganciclovir, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japanese Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Valganciclovir (VGCV) prophylaxis effectively prevents cytomegalovirus infection in lung transplant patients. However, VGCV‐induced neutropenia causes early cessation. Nucleoside diphosphate‐linked moiety X‐type motif (NUDT) 15 degrades the ganciclovir (GCV) triphosphate, an active metabolite. We assessed the effects of NUDT15 variants on neutropenia and VGCV cessation in recipients of lung transplants.

Methods

We recruited 28 patients who had received lung transplants and VGCV prophylaxis and genotyped NUDT15 exons 1–3 using Sanger sequencing. Neutrophil counts were monitored from 1 month to 1 year in the wild‐type and NUDT15 reduced‐function variant groups. Cumulative incidences of neutropenia (< 1500/mm 3 ) and neutropenia‐related cessation within 1 year, including late‐onset neutropenia, were assessed using Kaplan–Meier analysis. A subgroup analysis was conducted focusing on patients with stable renal function, the primary route of excretion for GCV.

Results

Of the 28 patients, nine carried NUDT15 variants (Arg139Cys, Val18Ile, Val18_Val19insGlyVal, Arg139Cys/Val18Ile). The neutrophil count nadir within 1 month of treatment was lower in the NUDT15‐variant group than in the wild‐type group. A higher incidence of neutropenia and VGCV cessation was observed in the NUDT15‐variant group, but without statistical significance. Among 13 patients with stable renal function, all four in the NUDT15‐variant group developed neutropenia and cessation within 60 days, compared with two of nine in the wild‐type group. Covariance analysis showed that NUDT15 variants were associated with decreased neutrophil counts, independent of GCV trough concentration.

Conclusion

NUDT15 variants increase the risk of early neutropenia during VGCV prophylaxis in lung transplant recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationNeutropeniaValganciclovirAntiviral AgentsCytomegalovirus InfectionsPyrophosphatasesGanciclovirHumansMaleFemaleMiddle AgedAdultRisk FactorsAgedPolymorphism, GeneticNudix Hydrolases

Stichwörter der Autor:innen

cytomegaloviruslung transplantationnucleoside diphosphate‐linked moiety X‐type motif 15prophylaxistherapeutic drug monitoringvalganciclovir

Substanzen

ValganciclovirAntiviral AgentsNUDT15 protein, humanPyrophosphatasesGanciclovirNudix Hydrolases

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Department of Infection Control and Prevention, Kyoto University Hospital, Kyoto, Japan.
  • Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

ORCID-Profile: Yurie Katsube

Förderung

  • Japanese Society for the Promotion of Science

Zitieren

APA

Katsube, Y., Umemura, K., Urabe, Y., Ono, M., Katada, Y., Hira, D., Ohsumi, A., Nakajima, D., Tsuda, M., Nakagawa, S., Mizuno, T., Nagao, M., Date, H., & Terada, T. (2025). NUDT15 Genetic Polymorphism as a Risk Factor for Early Neutropenia During Valganciclovir Prophylaxis in Lung Transplant Patients. Transplant Infectious Disease. https://doi.org/10.1111/tid.70108

Vancouver

Katsube Y, Umemura K, Urabe Y, Ono M, Katada Y, Hira D, et al. NUDT15 Genetic Polymorphism as a Risk Factor for Early Neutropenia During Valganciclovir Prophylaxis in Lung Transplant Patients. Transplant Infectious Disease. 2025. doi:10.1111/tid.70108

BibTeX
@article{Katsube2025,
  author = {Katsube, Yurie and Umemura, Keisuke and Urabe, Yuzuki and Ono, Miori and Katada, Yoshiki and Hira, Daiki and Ohsumi, Akihiro and Nakajima, Daisuke and Tsuda, Masahiro and Nakagawa, Shunsaku and Mizuno, Tomoyuki and Nagao, Miki and Date, Hiroshi and Terada, Tomohiro},
  title = {NUDT15 Genetic Polymorphism as a Risk Factor for Early Neutropenia During Valganciclovir Prophylaxis in Lung Transplant Patients},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70108}
}
Kostenlos starten →